Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Drugs In Development, 2022, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.
Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 30, 12, 1, 36 and 8 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.
Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Nephropathy - Overview
Diabetic Nephropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Nephropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Nephropathy - Companies Involved in Therapeutics Development
Diabetic Nephropathy - Drug Profiles
Diabetic Nephropathy - Dormant Projects
Diabetic Nephropathy - Discontinued Products
Diabetic Nephropathy - Product Development Milestones
Featured News & Press Releases
Feb 28, 2022: Goldfinch Bio announces positive preliminary data from phase 2 clinical trial evaluating GFB-887 as a precision medicine for patients with focal segmental glomerular sclerosis (FSGS)
Nov 08, 2021: Goldfinch Bio showcases biology, genetic and clinical programs at ASN Kidney Week demonstrating leadership in precision medicines for kidney diseases
Sep 17, 2021: adMare Portfolio Company, Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 Blocker
Sep 07, 2021: Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 blocker
Sep 01, 2021: XORTX announces grant of European patent supporting diabetic nephropathy
Aug 28, 2021: Bayer announces KERENDIA (finerenone) reduces the risk of cardiovascular outcomes in new phase III FIGARO-DKD study in adults with chronic kidney disease (Stages 1-4) associated with type 2 diabetes
Aug 17, 2021: Bayer to present late breaking data from Phase III FIGARO-DKD (finerenone) studies
Aug 02, 2021: Shanghai Pharmaceuticals SPH3127 tablets new indications received phase II clinical trial approval notice
Jul 27, 2021: Goldfinch Bio announces upcoming presentations at the 13th International Podocyte Conference
Jun 22, 2021: Caladrius Biosciences to assess its CLBS201 CD34+ cell therapy in diabetic kidney disease
May 13, 2021: Goldfinch Bio initiates phase 1 clinical trial of GFB-024, a novel precision medicine product candidate for patients with severe insulin resistant Diabetic Nephropathy (DN)
Mar 31, 2021: Mitsubishi Tanabe Pharma wins patent infringement lawsuit of Canagliflozin Hydrate in the U.S. district court
Feb 26, 2021: Canagliflozin (TA-7284) has been approved in Taiwan for diabetic nephropathy
Sep 21, 2020: New study offers hope for patients with diabetes and advanced kidney disease
Sep 08, 2020: Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, may be a new therapeutic agent for diabetic kidney disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Nephropathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Diabetic Nephropathy - Pipeline by Aadi Bioscience Inc, 2022
Diabetic Nephropathy - Pipeline by AIBIOS Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Akebia Therapeutics Inc, 2022
Diabetic Nephropathy - Pipeline by Algomedix Inc, 2022
Diabetic Nephropathy - Pipeline by Anagenics Ltd, 2022
Diabetic Nephropathy - Pipeline by APT Therapeutics Inc, 2022
Diabetic Nephropathy - Pipeline by AptaBio Therapeutics Inc, 2022
Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, 2022
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, 2022
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, 2022
Diabetic Nephropathy - Pipeline by Bayer AG, 2022
Diabetic Nephropathy - Pipeline by Betagenon AB, 2022
Diabetic Nephropathy - Pipeline by Bird Rock Bio Inc, 2022
Diabetic Nephropathy - Pipeline by BLR Bio LLC, 2022
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim International GmbH, 2022
Diabetic Nephropathy - Pipeline by Bristol-Myers Squibb Co, 2022
Diabetic Nephropathy - Pipeline by Caladrius Biosciences Inc, 2022
Diabetic Nephropathy - Pipeline by CCRP Therapeutics GmbH, 2022
Diabetic Nephropathy - Pipeline by Certa Therapeutics Pty Ltd, 2022
Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, 2022
Diabetic Nephropathy - Pipeline by Chinook Therapeutics Inc, 2022
Diabetic Nephropathy - Pipeline by Corbus Pharmaceuticals Inc, 2022
Diabetic Nephropathy - Pipeline by CSL Ltd, 2022
Diabetic Nephropathy - Pipeline by Curacle Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, 2022
Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, 2022
Diabetic Nephropathy - Pipeline by Dimerix Ltd, 2022
Diabetic Nephropathy - Pipeline by Frontbio Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Future Medicine Co Ltd, 2022
Diabetic Nephropathy - Pipeline by GenKyoTex SA, 2022
Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, 2022
Diabetic Nephropathy - Pipeline by Glycadia Inc, 2022
Diabetic Nephropathy - Pipeline by Gmax Biopharm LLC, 2022
Diabetic Nephropathy - Pipeline by GNI Group Ltd, 2022
Diabetic Nephropathy - Pipeline by Goldfinch Bio Inc, 2022
Diabetic Nephropathy - Pipeline by Guangdong East Sunshine Pharmaceutical Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Guangzhou Nanxin Pharmaceutical Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Hua Medicine Shanghai Ltd, 2022
Diabetic Nephropathy - Pipeline by Inovio Pharmaceuticals Inc, 2022
Diabetic Nephropathy - Pipeline by InSilico Medicine, 2022
Diabetic Nephropathy - Pipeline by Inversago Pharma Inc, 2022
Diabetic Nephropathy - Pipeline by Johnson & Johnson, 2022
Diabetic Nephropathy - Pipeline by Landos Biopharma Inc, 2022
Diabetic Nephropathy - Pipeline by MediPost Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Merck & Co Inc, 2022
Diabetic Nephropathy - Pipeline by Mesoblast Ltd, 2022
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Diabetic Nephropathy - Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Novartis AG, 2022
Diabetic Nephropathy - Pipeline by Novo Nordisk AS, 2022
Diabetic Nephropathy - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Orbsen Therapeutics Ltd, 2022
Diabetic Nephropathy - Pipeline by PhytoHealth Corp, 2022
Diabetic Nephropathy - Pipeline by Poxel SA, 2022
Diabetic Nephropathy - Pipeline by Praetego Inc, 2022
Diabetic Nephropathy - Pipeline by ProKidney LLC, 2022
Diabetic Nephropathy - Pipeline by RAGE Biotech Pty Ltd, 2022
Diabetic Nephropathy - Pipeline by Reata Pharmaceuticals Inc, 2022
Diabetic Nephropathy - Pipeline by Rebus Holdings Inc, 2022
Diabetic Nephropathy - Pipeline by Scohia Pharma Inc, 2022
Diabetic Nephropathy - Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2022
Diabetic Nephropathy - Pipeline by Serodus ASA, 2022
Diabetic Nephropathy - Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2022
Diabetic Nephropathy - Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
Diabetic Nephropathy - Pipeline by siRNAgen Therapeutics Corp, 2022
Diabetic Nephropathy - Pipeline by Slate Bio Inc, 2022
Diabetic Nephropathy - Pipeline by Sulfateq BV, 2022
Diabetic Nephropathy - Pipeline by Unicyte AG, 2022
Diabetic Nephropathy - Pipeline by Vidasym Inc, 2022
Diabetic Nephropathy - Pipeline by Wuhan Hamilton Bio-technology Co Ltd, 2022
Diabetic Nephropathy - Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022
Diabetic Nephropathy - Pipeline by XORTX Therapeutics Inc, 2022
Diabetic Nephropathy - Pipeline by ZyVersa Therapeutics Inc, 2022
Diabetic Nephropathy - Dormant Projects, 2022
Diabetic Nephropathy - Discontinued Products, 2022
List of Figures
Number of Products under Development for Diabetic Nephropathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
